Fed. Circ. Won't Revisit Restasis Patent Ruling
The Federal Circuit refused Wednesday to rethink a panel's ruling that Allergan and the St. Regis Mohawk Tribe's patents for the dry-eye drug Restasis are invalid, leaving in place a win for...To view the full article, register now.
Already a subscriber? Click here to view full article